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Abstract
Background: HBO1 (histone acetyltransferase binding to ORC1) is a histone acetyltransferase (HAT) which could
exert oncogenic function in breast cancer. However, the biological role and underlying mechanism of HBO1 in
breast cancer remains largely unknown. In the current study, we aimed to investigate the role of HBO1 in breast
cancer and uncover the underlying molecular mechanism.
Methods: Immunohistochemistry was applied to detect HBO1 protein expression in breast cancer specimens
(n = 112). The expression of protein level was scored by integral optical density (IOD) for further statistical analyses
using SPSS. Real-time PCR was used to simultaneously measure mRNA levels of HBO1. The HBO1 protein
expression in breast cancer cells was confirmed by western blot.
Results: HBO1 was highly expressed in breast cancer tissues and significantly correlated with estrogen receptor a
(ERa) (p < 0.001) and progestational hormone (PR) (p = 0.002). HBO1 protein level also correlated positively with
histology grade in ERa positive tumors (p = 0.016) rather than ERa negative tumors. 17b-estradiol (E2) could
upregulate HBO1 gene expression which was significantly inhibited by ICI 182,780 or ERa RNAi. E2-increased HBO1
protein expression was significantly suppressed by treatment with inhibitor of MEK1/2 (U0126) in T47 D and MCF-7
cells.
Conclusions: HBO1 was an important downstream molecule of ERa, and ERK1/2 signaling pathway may involved
in the expression of HBO1 increased by E2.
Background
Breast cancer is a major public health issue, with more
than one million new cases observed around the world in
2002 [1]. The pathogenesis of breast cancer is quite com-
plex. Lifetime exposure to estrogen is reported to be asso-
ciated with women’s risk for breast cancer and the
biological actions of estrogens are mediated primarily by
ERa which belongs to the nuclear receptor superfamily, a
family of ligand-regulated transcription factors [2-4]. ERa,
which promotes cell growth, metastasis and also mediates
resistance to apoptosis, plays a key role in progression of
breast cancer [5,6].
HBO1 (histone acetyltransferase binding to ORC1), also
named MYST2, belongs to the MYST family which is
characterized by a highly conserved C2HC zinc finger and
a putative histone acetyltransferase domain. The role of
HBO1 in cancer remains unclear, although its expression
has been reported in testicular germ cell tumors, breast
adenocarcinomas, and ovarian serous carcinomas [7].
Recent investigations have revealed that over-expression
of HBO1 dramatically enhances the anchorage-indepen-
dent growth of both MCF7 and SKBR3 breast cancer cells
[8]. Furthermore, it also functions as a transcriptional
coactivator for hormone receptors including ERa and PR
[9], leading to consideration of this protein as a carcinoge-
netic factor.
To elucidate the role of HBO1 in breast cancer, 112
breast cancer specimens were investigated using immu-
nohistochemistry with an anti-HBO1 antibody. We
found that HBO1 was notably increased in breast cancer.
E2-upregulated HBO1 expression could be inhibited by
ICI 182,780 or ERa RNAi in breast cancer cells.
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pathway was involved in the expression of HBO1
increased by E2.
Methods
Materials
Dulbecco’s modified Eagle’s medium (DMEM), phenol red-
free DMEM (PR-free DMEM), U0126 and 17b-estradiol
(E2) were purchased from Sigma. Lipofectamine 2000, Tri-
zol Reagent and fetal bovine serum (FBS) were purchased
from Invitrogen. Charcoal-stripped fetal bovine serum
(CS-FBS) was purchased from Biowest. PVDF membrane,
leupeptin, aprotinin, phenylmethylsulfonyl fluoride (PMSF)
and X-tremeGENE siRNA Transfection Reagent were pur-
chased from Roche. RNA PCR Kit (AMV) Ver.3.0 was pur-
chased from TaKaRa. Polinl-2-plus kit was a product of
GBI. Anti-phospho-ERK1/2 (Thr202/Tyr204) and anti-
ERK1/2 antibodies were purch a s e df r o mC e l lS i g n a l i n g
Technology. ERa siRNA, mouse monoclonal anti-ERa,
anti-GAPDH, horseradish peroxidase (HRP)-conjugated
goat anti-rabbit and HRP-conjugated goat anti-mouse IgG
secondary antibodies were from Santa Cruz Biotechnology.
Rabbit polyclonal anti-HBO1 antibody (Catalog No: 13751-
1-AP) was purchased from Protein Tech Group, Inc. The
enhanced chemiluminescence (ECL) assay kit was pur-
chased from Tiangen. Dual-luciferase reporter assay system
was bought from Promega. ICI 182,780 was purchased
from Tocris Bioscience.
Cell culture and transfection
Human MCF-7, T47 D, MDA-MB-453 and MDA-MB-
435 breast cancer cells were obtained from the Cell Bank
of Type Culture Collection of Chinese Academy of
Sciences. MCF-7 cells were cultured in DMEM supple-
mented with 10% fetal calf serum (FBS), 10 ug/ml of insu-
lin, 100 U/ml of penicillin and 50 ug/ml of streptomycin.
T47 D cells were maintained in DMEM supplemented
with 10% FBS, 100 U/ml of penicillin and 50 ug/ml strep-
tomycin. SiRNA was transfected with X-tremeGENE
siRNA Transfection Reagent according to the manufac-
ture’si n s t r u c t i o n s .
Western blot analyses
Proteins were detected by western blot analysis as
described previously [10]. The cells were lysed by lysis buf-
fer, separated in 10% SDS-PAGE and then transferred to a
PVDF membrane. The membrane was incubated with pri-
mary antibody followed by incubation with horseradish
peroxidase-conjugated secondary antibody. Then the
membrane was developed using the ECL detection system.
Tissue samples
112 primary breast cancer specimens were consecutively
obtained from pathological archives of Huashan Hospital,
Fudan University from 2005 to 2008. There was no any
bias for selection. Tissues were formalin-fixed and paraf-
fin-embedded for histopathologic diagnosis and immuno-
histochemical study. The malignancy degree of tumor
was scored according to the Scarff-Bloom-Richardson
system.
Immunohistochemistry (IHC)
Serial sections (5 μm thick) were mounted on glass
slides coated with 10% polylysine. Sections were
dewaxed in xylene and rehydrated in graded ethanol.
Endogenous peroxidase activity was blocked by immer-
sion in 0.3% methanolic peroxide for 30 minutes. Next,
sections were microwaved in citrate buffer for antigen
retrieval. Rabbit polyclonal anti-HBO1 (1:100 dilutions)
was used as primary antibodies. Staining was com-
pleted with Polink-2-plus kit, in accordance with the
manufacturer’s instructions. Color reaction product
was developed with diaminobenzidine. All sections
were counterstained with hematoxylin. Two patholo-
gists separately blinded to the clinical outcome of the
patients evaluated all samples. The immunoreactivity
intensity was evaluated as 0 (absent); 1 (weak nuclear
staining); 2 (moderate nuclear staining of intermediate
level); 3 (more coarse nuclear staining). Positive cells
were quantified as a percentage of the total number of
tumor cells with observation of 1000 cells in 5 high
power field (×400), and assigned to one of five cate-
gories: 0: < 5%, 1: 5-25%, 2: 26-50%, 3: 51-75% and 4:
> 75%. HBO1 expression was scored semi-quantita-
tively using the Remmele-score (immunoreactive score
(IS) = score of percentage of positive tumor cells ×
score of staining intensity). Then the slide of IS > 3
was classified as a positive case [11]. Reproducibility
of the scoring method used by both observers was
greater than 95%.
Total RNA extraction and real-time PCR
Total mRNA samples of T47 D and MCF-7 breast cancer
cells were extracted using trizol reagent according to the
manufacturer’s instructions. One microgram of total
RNA extracted from the cells was subjected to reverse
transcription (RT). The RT and real-time PCR were per-
formed by using TaKaRa RNA PCR Kit (AMV) Ver.3.0
and SYBR Premix Ex Taq II according to the manual
respectively. Primers used for real-time PCR were as fol-
l o w s :H B O 1 - F5 ’-GATGCCCACTGTATCATAACC-3’
and HBO1-R 5’-TTCTTCCTGAGTTCAGCCACT-3’;
GAPDH-F 5’-GGCTGAGAACGGGAAGCTTGTCAT-3’
and GAPDH-R 5’-CAGCCTTCTCCATGGTGGT-
GAAGA-3’. Real-time PCR was performed using 7500
multicolor real-time PCR detection system (ABI) with
the following cycling conditions: (i) 30s at 95°C and (ii)
40 cycles, with 1 cycle consisting of 5s at 95°C, 34s at
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the same experimental conditions. Data were analyzed by
using 7500 software (ABI). The values were obtained
through normalizing to GAPDH copies.
Statistical analysis
Statistical data analyses were performed using SPSS 11.5
statistical software package. The relationship between pro-
tein levels and different clinical and pathological features
were explored using cross tabulation and Pearson’sx
2.
P values less than 0.05 were selected.
Results
HBO1 protein level correlates positively with ERa
In order to explore the biological role of HBO1 in human
breast cancer in vivo, we examined the expression of
HBO1 in tumor samples of primary breast cancer (n =
112) by IHC analysis. We found that HBO1 which was
predominantly detected in nucleus (Figure 1B-C) was
highly expressed in breast cancer tissues (Table 1) and sig-
nificantly correlated with ERa (p < 0.001) and PR (p =
0.002) (Table 2). Further statistical analysis revealed HBO1
protein level correlated positively with histology grade in
ERa positive tumors (p = 0.016) rather than ERa negative
tumors (Table 2). For benign breast tissues, low HBO1
immunoreactivity was observed and epithelial cells dis-
played a minimal granular staining (Figure 1A). Moder-
ately and poorly differentiated breast cancer tissues
showed intense HBO1 staining (Figure 1B-C). To further
study the relationship between HBO1 and ERa, we exam-
ined HBO1 expression level in several breast cancer cell
lines by western blot, which showed that ERa positive
breast cancer cell lines exhibited higher HBO1 protein
than ERa negative breast cancer cell lines (Figure 1D).
E2 induces HBO1 expression in breast cancer cells
In order to further investigate the relationship between
ERa and HBO1, we treated breast cancer cells with
Figure 1 Expression of HBO1 in human breast cancer. (A) Immunohistochemical staining for HBO1 in benign breast epithelial tissues
(magnification: A, 400×). (B) Moderately differentiated breast cancer tissues (brown staining) (magnification: B, 400×). (C) Poorly differentiated
breast cancer tissues (brown staining) (magnification: C, 400×). (D) HBO1 protein level in several breast cancer cell lines based on the western
blot results.
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to determine the effect of E2 on the mRNA level of
HBO1. With the dose of E2 increasing from 10
-9 to 10
-7
M, the mRNA level of HBO1 gradually increased and
reached a plateau at 10
-8 M in T47 D cells (Figure 2A).
Hereby, 10
-8 M of E2 was applied for all subsequent
experiments. Western blot was also performed to con-
firm that E2 could upregulate HBO1 protein expression
in T47 D (Figure 2B) and MCF-7 cells (Figure 2C).
Taken together, these results demonstrated that E2
increased expression of HBO1 at transcriptional level.
E2-induced HBO1 expression is inhibited by ICI 182,780
or ERa RNAi
To further study the role of ERa in HBO1 expression,
ICI 182,780 was further applied in T47 D cells (Figure
3A) and MCF-7 cells (Figure 3B) to block the effect of
E2. As shown in Figure 3A, E2 increased HBO1 protein
expression (lane 2), which was significantly reduced by
ICI 182,780 (lane 4). Similar results were obtained in
MCF-7 cells (Figure 3B). ICI 182,780 was reported to
act by binding ERa, causing disassociation of ERa asso-
ciated proteins and resulting in impaired receptor
dimerisation and increased receptor degradation [12,13].
As expected, ERa expression was decreased by ICI
182,780 (Figure 3A and 3B). These results indicated that
E2-induced HBO1 upregulation could be inhibited by
I C I1 8 2 , 7 8 0 .I no r d e rt of i g u r eo u tt h er o l eo fE R a in
E2-induced HBO1 upregulation, ERa siRNA was trans-
fected into T47 D and MCF7 cells to knockdown ERa.
We observed that E2-induced HBO1 upregulation was
inhibited by ERa siRNA (lane 4), indicating that HBO1
might be a downstream signaling molecule for ERa.
ERK1/2 signaling pathway was involved in the expression
of HBO1 increased by E2
Using TRSEARCH software based on the sequence data-
base, the promoter region of the HBO1 gene has no
putative binding sites for ERa (data not shown). And
previous studies have shown that steroidal estrogens are
able to rapidly and transiently activate the ERK1/2 path-
way [13], so we examined whether the ERK1/2 pathway
was involved in the effect of E2 on HBO1 expression in
breast cancer cells. As shown in Figure 4, E2-increased
HBO1 protein expression was significantly suppressed
Table 1 Clinical and pathological characteristics of
patients
characteristic value
Tumor grade (n[%])
I 45 [40.2%]
II/III 67 [59.8%]
Ki67 status (n[%])
negative 50 [44.6%]
positive 62 [55.4%]
Estrogen receptor a status (n[%])
negative 39 [34.8%]
positive 73 [65.2%]
Progesterone receptor status (n[%])
negative 60 [53.6%]
positive 52 [46.4%]
P53 status (n[%])
Negative 62 [55.4%]
Positive 50 [44.6%]
HBO1 status (n[%])
negative 48 [42.9%]
positive 64 [57.1%]
Histology Grade (n[%])
G1 32 [28.6%]
G2/G3 80 [71.4%]
Table 2 Expression of HBO1 in relation to the clinical and
pathological characteristics of patients
clinical feature total HBO1 expression P-value
negative positive
Tumor grade
I 45 21 24 0.610
II/III 67 28 39
Ki67
negative 50 23 27 0.550
positive 62 25 37
Estrogen receptor
negative 39 26 13 < 0.001**
positive 73 22 51
Progesterone receptor
negative 60 34 26 0.002**
positive 52 14 38
P53
negative 62 23 39 0.170
positive 50 25 25
Histology Grade
G1 32 17 15 0.165
G2/G3 80 31 49
among ER positive tumors
Histology Grade
G1 25 12 13 0.016*
G2/G3 48 10 38
among ER negative tumors
Histology Grade
G1 8 5 3 0.779
G2/G3 31 21 10
*P < 0.05 **P < 0.01
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D (Figure 4A) and MCF-7 (Figure 4B) cells as analyzed
by western blot. These results indicated that ERK1/2
signaling pathway was involved in the E2-induced
HBO1 upregulation in breast cancer cells.
Discussion
HBO1 is a potential oncogene which maps to17q21.3, a
region where frequent allelic gains are found in breast
cancers and this amplification is associated with a poor
prognosis of clinical outcome [14-16]. Previous studies
demonstrated over-expression of HBO1 dramatically
enhanced the anchorage-independent growth of both
MCF7 and SKBR3 breast cancer cells while depletion of
HBO1 reduced the rate of DNA synthesis, the amount
of MCM complex bound to chromatin, and progression
through S phase. HBO1 has also been shown to enhance
transcription mediated by steroid receptors including
ERa and PR [9]. However, little is known about the role
of HBO1 in breast cancer and the underlying molecular
mechanism.
In this study, we first investigated the HBO1 protein
expression in large numbers of tumor samples of
Figure 2 E2 induces HBO1 expression in breast cancer Cells. (A)
T47 D Cells were treated with E2 (10
-9,1 0
-8,1 0
-7 M) for 24 hours
and mRNA level was quantified by real-time PCR analysis. (B) T47 D
cell were treated with E2 (10
-9,1 0
-8,1 0
-7 M) for 24 hours and
western blot. Results quantitated by densitometric analysis were
representative of three repeated experiments. (C) MCF-7 cells were
treated with E2 (10
-9,1 0
-8,1 0
-7 M) for 24 hours and western blot.
Results quantitated by densitometric analysis were representative of
three repeated experiments.
Figure 3 E2-induced HBO1 expression is inhibited by ICI
182,780 or ERa RNAi. (A) T47 D cells were treated with E2 (10
-8
M), ICI 182,780 (1 uM), or E2 (10
-8 M) plus ICI 182,780 (1 uM) for
24 hours. Then total cell lysates were processed for western blot
analysis as described in Methods. GAPDH was used as an internal
control. (B) MCF-7 cells were treated with E2 (10
-8 M), ICI 182,780
(1 uM), or E2 (10
-8 M) plus ICI 182,780 (1 uM) for 24 hours. Then
total cell lysates were processed for western blot analysis as
described in Methods. GAPDH was used as an internal control.
(C) T47 D cells were transiently transfected with scrambled siRNA or
ERa siRNA. 48 h later, total cell lysates were processed for western
blot analysis as described in Methods. (D) MCF-7 cells were
transiently transfected with scrambled siRNA or ERa siRNA. 48 h
later, total cell lysates were processed for western blot analysis as
described in Methods.
Figure 4 E2 enhances HBO1 expression through ERK1/2
signaling pathways. (A) Serum-starved T47 D cells were treated
with E2 (10
-8 M), or U0126 (10 uM) plus E2 (10
-8 M) for 24 hours.
Then equal amounts of protein (lysates) were subjected to SDS-
PAGE. Western blot was performed using the Anti-phospho-ERK1/2
(Thr202/Tyr204), anti-HBO1 and anti-ERK1/2 antibodies. GAPDH was
used as an internal control. (B) Serum-starved MCF-7 cells were
treated with E2 (10
-8 M), or U0126 (10 uM) plus E2 (10
-8 M) for 24
hours. Western blot was performed as described in (A).
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showed that HBO1 was highly expressed in breast can-
cer (Table 1) and positively correlated with ERa (p <
0.001) and PR (p = 0.002). Moreover, HBO1 protein
level correlated positively with histology grade in ER
positive tumors (p = 0.016) rather than ERa negative
tumors through statistical analysis. As a coactivator of
the replication licensing factor Cdt1 [17], HBO1 belongs
to one component of the Replication Initiation Proteins
known as prereplicative complex (pre-RC) proteins. Sev-
eral pre-RC proteins are over-expressed in cancer and
serve as good tumor markers. And some of them, such
as Cdc6 and Cdt1, are elevated by E2 treatment in
breast cancer. To determine whether HBO1 was also
affected by E2, quantitative real-time PCR and western
blot were performed. The results suggested HBO1 was
elevated after E2 treatment. Further study demonstrated
the E2-induced HBO1 upregulation could be inhibited
by ICI 182,780 as well as ERa siRNA.
Estrogen receptor (ER) signaling is involved in many
human diseases such as breast cancer [18], lung cancer
[19,20] and cardiovascular diseases [21,22]. It was
reported that E2 activated the signal-transducing ERK1/2
pathway, which were critical for cell proliferation [23-25],
in human mammary cancer-derived cell lines, MCF-7
and T47 D [26-28]. We explored whether ERK1/2 signal-
ing pathway was involved in the expression of HBO1
increased by E2. The MEK1/2 inhibitor U0126 signifi-
cantly inhibited the expression of HBO1 in T47 D and
MCF-7 cells, suggesting that E2 increased the expression
of HBO1 through the ERK1/2 signaling pathway. Since
previous studies have shown that progesterone receptor
activates the Src/p21ras/ERK pathway via cross-talk with
estrogen receptor in breast cancer [29], the positive cor-
relation between HBO1 protein levels and PR which we
obtained in statistical analysis was reasonable.
Estrogen exposure has been regarded as high risk factor
of breast cancer. It has been reported that HBO1 strongly
enhanced ER-mediated transcription [9], which indicated
that HBO1 might play a role in the progress of breast
cancer. In this study, we proved E2 could upregulate the
mRNA and protein level of HBO1. Meanwhile, knock-
down of ERa with siRNA significantly inhibited the upre-
gulation of HBO1, indicating that cross-talking was
happening between ERa and HBO1 in breast cancer, the
biological functions of which need to be further studied.
Conclusion
Our data have demonstrated that the HBO1 protein
levels correlated positively with ERa (p < 0.001) and PR
(p = 0.002) expression in breast cancer. Further more,
HBO1 protein levels correlated positively with histology
grade in ERa positive tumors (p = 0.016). We also
showed that the ERK1/2 signaling pathway was involved
in the expression of HBO1 increased by E2. These find-
ings suggested a potential for targeting HBO1 as a novel
means of breast cancer therapy as well as a potential
diagnosis marker for ERa positive breast cancer.
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